Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Goldinger, SM; Zimmer, L; Schulz, C; Ugurel, S; Hoeller, C; Kaehler, KC; Schadendorf, D; Hassel, JC; Becker, J; Hauschild, A; Dummer, R; Dermatology Cooperative Oncology Group (DeCOG).
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Eur J Cancer. 2014; 50(2):406-410
Doi: 10.1016/j.ejca.2013.09.014
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Becker Jürgen Christian
- Ugurel-Becker Selma
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BRAF-mutant melanoma can be successfully treated by BRAF kinase inhibitors (BRAFi) and MEK kinase inhibitors (MEKi). However, the administration of BRAFi followed by MEKi did not generate promising response rate (RR). The purpose of this investigation was to evaluate the time to progression (TTP) with a mitogen-activated protein kinase (MAPK) pathway upstream inhibition strategy in BRAF mutated melanoma patients. BRAF mutation positive metastatic melanoma patients were identified within the Dermatology Cooperative Oncology Group (DeCOG) network and were treated first with a MEKi and upon progression with a selective BRAFi. A total of 23 melanoma patients (six females, 17 males, aged 47-80 years) were retrospectively analysed for TTP. The total median TTP was 8.9 months. The median TTP for MEKi was 4.8 (1.2-23.2) and subsequent for BRAFi 4.5 (1.2-15.7) months, respectively. A higher RR for MEKi (39%, nine partial responses and 0 complete responses) than previously reported was observed. Our analysis suggests that the reversed inhibition of the MAPK pathway is feasible in BRAF mutated melanoma. The median TTP (8.9 months) is close to the promising BRAF- and MEKi combination therapy (median progression-free survival (PFS) 9.4 months). The total treatment duration of the MAPK inhibition when a MEKi is administered first is similar compared to the reversed sequence, but TTP shifts in favour to the MEKi. This approach is feasible with reasonable tolerability. This clinical investigation encourages further studies in prospective clinical trials to define the optimal treatment schedule for the MAPK pathway inhibition and should be accompanied by molecular monitoring using repeated biopsies. Copyright © 2013 Elsevier Ltd. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged, 80 and over -
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Benzimidazoles - administration & dosage
- Disease Progression -
- Disease-Free Survival -
- Feasibility Studies -
- Female -
- Humans -
- Imidazoles - administration & dosage
- Indoles - administration & dosage
- MAP Kinase Signaling System - drug effects
- Male -
- Melanoma - drug therapy
- Melanoma - genetics
- Middle Aged -
- Mitogen-Activated Protein Kinases - antagonists & inhibitors
- Mitogen-Activated Protein Kinases - metabolism
- Mutation -
- Outcome Assessment (Health Care) - methods
- Oximes - administration & dosage
- Protein Kinase Inhibitors - administration & dosage
- Proto-Oncogene Proteins B-raf - antagonists & inhibitors
- Proto-Oncogene Proteins B-raf - genetics
- Proto-Oncogene Proteins B-raf - metabolism
- Pyridones - administration & dosage
- Pyrimidinones - administration & dosage
- Retrospective Studies -
- Sulfonamides - administration & dosage
- Time Factors -
- Vemurafenib -
- Find related publications in this database (Keywords)
- BRAF inhibitor
- MEK inhibitor
- Melanoma
- MAPK pathway
- Upstream inhibition
- Downstream inhibition
- Sequenced administration